Micromet, Inc. Replay of Third Quarter 2009 Financial Results Conference Call Now Available

BETHESDA, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announces that a replay of the Third Quarter 2009 Financial Results conference call is now immediately available.

To access the replay of the conference call dial 800-642-1687 (U.S.) or 706-645-9291 (international), passcode: 37942882.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Merck Serono, Nycomed and MedImmune.

The Micromet, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6805

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with sanofi-aventis, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with sanofi-aventis, the mode of action of BiTE antibodies, our development of blinatumomab, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by sanofi-aventis and under our termination agreement with MedImmune. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborators, including sanofi-aventis, MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates, and the risk of adverse outcomes of legal proceedings. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2009, filed with the SEC on August 6, 2009, as well as other filings by the company with the SEC.

CONTACT:  Micromet, Inc.
          US Media:
          Andrea tenBroek/Chris Stamm
            (781)-684-0770
            micromet@schwartz-pr.com
          US Investors:
          Susan Noonan
            (212) 966-3650
            susan@sanoonan.com
          European Media:
          Ludger Wess
            +49 (40) 8816 5964
            ludger@akampion.com
          European Investors:
          Ines-Regina Buth
            +49 (30) 2363 2768
            ines@akampion.com